GlassScriptPhysician profile
Jocelyn Cavender
NPI 1558507087
$1,320.46
in general payments reported to CMS, 2019-2025
21 companies · $184 in 2025
The $184 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $559 · 2023: $24.61 · 2024: $554 · 2025: $184.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $762.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $761.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $500.60 | 2022-2025 | |
| Alkermes, INC. | $122.51 | 2022-2025 | Aristada, Lybalvi, Vivitrol |
| Tempus Ai, INC | $82.89 | 2024 | |
| Lundbeck LLC | $79.35 | 2022-2024 | Brintellix |
| Sunovion Pharmaceuticals INC. | $77.62 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $61.79 | 2022-2024 | Trintellix |
| Neurocrine Biosciences, INC. | $52.47 | 2022-2024 | Ingrezza |
| Hologic Sales and Service, LLC | $45.94 | 2024-2025 | Aptima, Thinprep 2000 Processor |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $45.29 | 2022-2024 | Caplyta |
| Axsome Therapeutics, INC. | $33.66 | 2024 | Auvelity |
| Exact Sciences Corporation | $24.61 | 2023 | Cologuard Collection Kit |
| Teva Pharmaceuticals USA, INC. | $22.55 | 2024 | Austedo Xr |
| Edwards Lifesciences Corporation | $21.60 | 2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Ironshore Pharmaceuticals INC. | $21.52 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $20.86 | 2024 | Airsupra |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $20.64 | 2025 | Zepbound, Mounjaro |
| Janssen Pharmaceuticals, INC | $18.98 | 2024 | Spravato |
| Cleerly, INC. | $18.39 | 2025 | Cleerly Labs, Cleerly Ischemia |
| Otsuka America Pharmaceutical, INC. | $17.63 | 2024 | Rexulti |
| Novo Nordisk INC | $16.32 | 2024 | Wegovy |
| Phadia US INC. | $15.24 | 2025 | Immunocap |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jocelyn Cavender listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.